Immunotherapy of Recurrent Cervical Cancers Using Dendritic Cells (DCs)

Launched by NATIONAL TAIWAN UNIVERSITY HOSPITAL · Sep 9, 2005

Keywords

ClinConnect Summary

Chemotherapy is the current standard treatment for unresectable recurrent cervical carcinoma after radiotherapy or distant metastasis of cervical carcinoma. The most effective regimens are cisplatin-based chemotherapy. After failure of the cisplatin-based chemotherapy, there is still no treatment that has been proved to be effective.

Human papilloma viruses (HPV) have been consistently implicated in causing cervical cancer especially those high-risk types (HPV 16,18,31,45) have been strongly associated with cervical cancer. HPV 16 was found in more than 50% of cervical cancer tissues. Resu...

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • 1. recurrent cervical cancer
• • 2. HPV 16 infection
• • 3. Previously received cisplatin ot 5-FU based chemotherapy or refused to receive chemotherapy
• • 4. HLA-A2 haplotype
• • 5. Older than 20 years old
• • 6. ECOG I or II
• • 7. Life expectancy longer than 3 months
• • 8. Adequate bone marrow reserve
• • 9. pregnancy test: negative
• • 10. Informed consent obtained
• Exclusion Criteria:
• • 1. CNS metastasis
• • 2. Acute or chronic infection
• • 3. Pregnant or lactating women
• • 4. Asthma
• • 5. Cardiac diseases such as heart failure, unstable angina, arrhythmia, myocardial infarction
• • 6. Autoimmune disease
• • 7. Previously other cancers (except basal cell cancer)
• • 8. Without chemotherapy, biotherapy for more than 6 weeks